Medplus Health Services Ltd
            ₹ 810
            
              
                
                -1.53%
              
            
          
          
            
              04 Nov
              
                4:01 p.m.
              
            
          
        About
          
          
            Key Points
            - Market Cap ₹ 9,700 Cr.
 - Current Price ₹ 810
 - High / Low ₹ 1,052 / 603
 - Stock P/E 185
 - Book Value ₹ 106
 - Dividend Yield 0.00 %
 - ROCE 4.58 %
 - ROE 3.32 %
 - Face Value ₹ 2.00
 
Pros
- Company is almost debt free.
 - Company has delivered good profit growth of 29.4% CAGR over last 5 years
 - Company's median sales growth is 46.8% of last 10 years
 
Cons
- Stock is trading at 7.57 times its book value
 - Though the company is reporting repeated profits, it is not paying out dividend
 - Company has a low return on equity of 1.57% over last 3 years.
 - Promoters have pledged or encumbered 59.3% of their holding.
 - Working capital days have increased from 53.4 days to 76.5 days
 
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
      Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | 2 | 2 | 9 | 10 | 61 | 68 | 146 | 214 | 467 | 713 | 768 | |
| 6 | 7 | 4 | 14 | 13 | 86 | 77 | 142 | 208 | 435 | 635 | 675 | |
| Operating Profit | -3 | -5 | -2 | -5 | -3 | -25 | -9 | 3 | 6 | 32 | 78 | 94 | 
| OPM % | -137% | -225% | -89% | -52% | -36% | -41% | -13% | 2% | 3% | 7% | 11% | 12% | 
| -1 | 1 | 0 | 1 | 1 | 2 | 2 | 10 | 23 | 7 | 9 | 10 | |
| Interest | 1 | 0 | 0 | 12 | 0 | 0 | 1 | 3 | 7 | 8 | 9 | 9 | 
| Depreciation | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 5 | 15 | 24 | 27 | 27 | 
| Profit before tax | -5 | -4 | -2 | -16 | -3 | -24 | -9 | 6 | 8 | 7 | 51 | 68 | 
| Tax % | 0% | 0% | 0% | 0% | 0% | 2% | 0% | 0% | 27% | -36% | 21% | |
| -5 | -4 | -2 | -16 | -3 | -25 | -9 | 6 | 6 | 9 | 40 | 53 | |
| EPS in Rs | -292.30 | -241.71 | -109.61 | -793.71 | -126.23 | -1,220.91 | -186.95 | 0.47 | 0.46 | 0.79 | 3.37 | 4.38 | 
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 77% | 
| 5 Years: | 63% | 
| 3 Years: | 70% | 
| TTM: | 22% | 
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 30% | 
| 5 Years: | 29% | 
| 3 Years: | 95% | 
| TTM: | 75% | 
| Stock Price CAGR | |
|---|---|
| 10 Years: | % | 
| 5 Years: | % | 
| 3 Years: | 12% | 
| 1 Year: | 22% | 
| Return on Equity | |
|---|---|
| 10 Years: | 0% | 
| 5 Years: | 1% | 
| 3 Years: | 2% | 
| Last Year: | 3% | 
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.17 | 0.17 | 0.17 | 0.19 | 0.19 | 0.19 | 0.45 | 24 | 24 | 24 | 24 | 24 | 
| Reserves | 126 | 108 | 88 | 185 | 185 | 395 | 517 | 1,089 | 1,117 | 1,164 | 1,216 | 1,252 | 
| 55 | 55 | 55 | 0 | 0 | 3 | 7 | 44 | 86 | 89 | 95 | 101 | |
| 6 | 21 | 39 | 3 | 6 | 17 | 24 | 30 | 45 | 33 | 65 | 52 | |
| Total Liabilities | 187 | 185 | 183 | 189 | 192 | 415 | 548 | 1,187 | 1,272 | 1,310 | 1,399 | 1,430 | 
| 1 | 1 | 0 | 0 | 0 | 7 | 23 | 85 | 179 | 192 | 184 | 184 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 16 | 18 | 0 | 1 | 1 | 
| Investments | 153 | 177 | 177 | 181 | 186 | 381 | 408 | 418 | 917 | 923 | 928 | 930 | 
| 34 | 6 | 5 | 8 | 5 | 26 | 115 | 668 | 157 | 196 | 286 | 314 | |
| Total Assets | 187 | 185 | 183 | 189 | 192 | 415 | 548 | 1,187 | 1,272 | 1,310 | 1,399 | 1,430 | 
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -5 | -4 | -2 | -1 | -1 | -0 | -6 | -18 | 11 | 8 | 47 | |
| -11 | -24 | 0 | -2 | -3 | -194 | -15 | -636 | 32 | -24 | -39 | |
| 46 | 0 | 0 | 7 | 0 | 204 | 97 | 569 | -8 | -6 | -10 | |
| Net Cash Flow | 30 | -28 | -1 | 4 | -4 | 10 | 76 | -86 | 35 | -22 | -2 | 
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 32 | 29 | 14 | 22 | 80 | 51 | 62 | 53 | 64 | 54 | 62 | 
| Inventory Days | 33 | 35 | 12 | 16 | 15 | 12 | |||||
| Days Payable | 9 | 17 | 17 | 30 | 19 | 30 | |||||
| Cash Conversion Cycle | 32 | 29 | 14 | 22 | 80 | 75 | 79 | 48 | 50 | 50 | 44 | 
| Working Capital Days | -78 | -72 | -130 | -97 | -145 | -12 | -20 | 1,547 | 21 | 62 | 76 | 
| ROCE % | -2% | -1% | -2% | -1% | -8% | -2% | 1% | 1% | 1% | 5% | 
Documents
Announcements
- 
        
          Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
          
            2m - Audio of MedPlus Q2FY26 earnings call (03-Nov-2025) for quarter and H1 ended Sep 30, 2025.
 - 
        
          Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (LODR) Regulations, 2015
          
            1d - Optival store (Shanti Nagar, Nagpur) drug-license suspended 21 days; order dated 01.11.2025; potential revenue loss Rs4.34 lakh.
 - 
        
          Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (LODR) Regulations, 2015
          
            2d - Received two stay orders (Nagpur, Amravati) against suspension; dated Nov 01, 2025.
 - 
        
          Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (LODR) Regulations, 2015
          
            2d - Subsidiary’s Andhra Pradesh store drug license suspended seven days; order dated 31.10.2025; revenue loss ~Rs1.75 lakh.
 - Announcement under Regulation 30 (LODR)-Newspaper Publication 2d
 
Annual reports
Concalls
- 
      Oct 2025TranscriptNotesPPT
 - 
      Aug 2025Transcript PPT REC
 - 
      May 2025Transcript PPT REC
 - 
      Feb 2025Transcript PPT
 - 
      Nov 2024Transcript PPT REC
 - 
      Aug 2024Transcript PPT
 - 
      May 2024Transcript PPT
 - 
      Feb 2024TranscriptPPT
 - 
      Feb 2024Transcript PPT
 - 
      Nov 2023Transcript PPT
 - 
      Aug 2023Transcript PPT
 - 
      May 2023Transcript PPT
 - 
      Feb 2023Transcript PPT
 - 
      Feb 2023TranscriptNotesPPT
 - 
      Feb 2023TranscriptNotesPPT
 - 
      Nov 2022Transcript PPT
 - 
      Aug 2022TranscriptNotesPPT
 - 
      Jun 2022Transcript PPT
 - 
      Feb 2022TranscriptNotesPPT
 
India's Leading Pharmacy Company[1][2]
MedPlus is the 2nd largest pharmacy retailer in India, with 4,552 stores across 12 states and 1 union territory as of Q2 FY25. These stores are strategically distributed to maintain a high presence in metro, tier-one, and tier-two cities.
The stores increased with 108 net new stores added in Q2 FY2025, of which 71 were in Tier-2 and Tier-3 cities[3]